Houston oncology therapeutics co. raises $11.4M in seed funding

money moves

Diakonos Oncology Corp. closed its seed round to the tune of $11.4 million. Photo via Getty Images

A Houston-based, clinical-stage immuno-oncology company has raised an oversubscribed round of seed funding.

Diakonos Oncology Corp. closed its seed round to the tune of $11.4 million. The funding will go toward supporting the company's Phase 2 trial — slated for later this year, following its ongoing Phase 1 study — and operations through late next year. California-based biotechnology investment firm Restem Group Inc. led the round, and existing investors contributed as well.

“We greatly appreciate the support of these investors in sharing our passion for improving the lives of patients suffering from deadly cancers such as glioblastoma,” Mike Wicks, Diakonos CEO, says in a news release. “The fact that this financing is nearly triple our initial target also shows they share our confidence in the effectiveness of our unique cancer therapy.”

Founded in 2016, the company recently received FDA Fast Track designation for its dendritic cell vaccine, DOC1021, which targets glioblastoma multiforme, or GBM, the most common and most lethal malignant brain tumor in adults. Diakonos also received the designation for its pancreatic cancer treatment.

"We are thrilled to invest in this groundbreaking company that is at the forefront of cancer treatment innovation. As a firm deeply involved in the cell therapeutic field, we recognize the immense potential of their pioneering work with dendritic cell therapies and we are confident that this can become a new standard of care for cancer in the future," adds Andres Isaias, executive chairman of Restem Group Inc.

Diakonos Oncology's DOC1021 uses the body’s natural anti-viral immune response to fight GBM. The vaccine mimics viral infection with the patient’s cancer markers. Essentially, DOC1021 uses the body’s own natural ability to detect and eliminate infected cells. According to the company, all of the patients who have tried the treatment have exceeded survival expectations. And DOC1021 appears to be extremely safe, with no serious adverse effects having been reported.

From Your Site Articles
A Houston health care company received the green light from the FDA to advance a treatment that's targeting a deadly cancer. Photo via Getty Images

Houston immunotherapy company achieves FDA designation for cancer-fighting vaccine

got the green light

The FDA has granted a Houston-based company a Fast Track designation.

Diakonos Oncology Corp. is a clinical-stage immuno-oncology company that has developed a unique dendritic cell vaccine, DOC1021. The vaccine targets glioblastoma multiforme (GBM), the most common and most lethal malignant brain tumor in adults. The aggressive tumors come with a life expectancy of about 15 months following diagnosis. About 7 percent of those diagnosed survive five years, while the 10-year outlook only sees a one-percent survival rate.

“The FDA’s decision acknowledges the potential of this new treatment approach for a very challenging disease,” Diakonos CEO Mike Wicks says in a press release. “Our protocol represents a first for cancer immunotherapy and could be viable for many types of cancers beyond GBM.”

FDA Fast Track designations are intended to expedite the haste with which drugs with early clinical promise are reviewed, likely taking them to market faster.

DOC1021 uses the body’s natural anti-viral immune response to fight GBM. The vaccine mimics viral infection with the patient’s cancer markers. Essentially, DOC1021 uses the body’s own natural ability to detect and eliminate infected cells.

The technology uses dendritic cells, white blood cells that are able to perceive threats, to its advantage. The unique cancer markers are loaded both internally and externally into the immune cells, just as they would simultaneously occur in a viral infection. The individualized treatment is administered through three precise injections that target deep cervical lymph node chains. By dosing this way, the immune responses are directed straight to the central nervous system.

The results have spoken for themselves: All of the patients who have tried the treatment have exceeded survival expectations. And just as importantly, DOC1021 appears to be extremely safe. No serious adverse effects have been reported.

“Because Phase I clinical trials are generally not statistically powered to demonstrate efficacy, detection of a statistically significant efficacy signal is very promising,” says William Decker, associate professor of immunology at Baylor College of Medicine and inventor of the DOC1021 technology.

The Phase 1 open-label trial of DOC1021 (NCT04552886) is currently taking place at both the University of Texas Health Science Center in Houston and at the MD Anderson Cancer Center at Cooper University Health Care in Camden, NJ. The trial is expected to complete this year.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice University lands $14M state grant to open Center for Space Technologies

on a mission

Rice University’s Space Institute soon will be home to the newly created Center for Space Technologies.

On Feb. 17, the Texas Space Commission approved a nearly $14.2 million grant for the Rice project. The Center for Space Technologies will target:

  • Research and development
  • Technology transfer and innovation
  • Statewide partnerships
  • Workforce development training
  • Space-focused education programs

The goal of the new center “is to fulfill an articulated need for research, workforce development, and industry collaboration,” said Kemah communications and marketing executive Gwen Griffin, chair of the commission.

State Rep. Greg Bonnen, a Friendswood Republican, authored the bill that set up the Texas Space Commission.

Since being authorized in 2023, the commission has funded 24 projects, with Rice and Houston-area companies accounting for nearly $75 million in grants to back space-related initiatives.

The grant to Rice brings the TSC's total investment to $150 million, fully committing the entire state appropriation from the Texas Legislature in 2023.

Other local companies that have received grants over the years include Aegis Aerospace, Axiom Space, Intuitive Machines, Starlab Space and Venus Aerospace.

The commission also awarded $7 million to Blue Origin earlier this month. See a list of the 24 awards here.

Waymo self-driving robotaxis have officially launched in Houston

Waymo has arrived

Waymo will begin dispatching its robotaxis in four more cities in Texas and Florida, expanding the territory covered by its fleet of self-driving cars to 10 major U.S. metropolitan markets.

The move into Dallas, Houston, San Antonio and Orlando, Florida, announced Tuesday, February 24, widens Waymo's early lead in autonomous driving while rival services from Tesla and the Amazon-owned Zoox are still testing their vehicles in only a few U.S. cities.

In contrast, Waymo's robotaxis already provide more than 400,000 weekly trips in the six metropolitan areas where they have been transporting passengers: Phoenix, the San Francisco Bay Area, Los Angeles, Miami, Atlanta, and Austin, Texas.

Waymo operates its ride-hailing service through its own app in all the U.S. cities except Atlanta and Austin, where its robotaxis can only be summoned through Uber's ride-hailing service.

The expansion into four more markets marks a significant step toward Waymo's goal to surpass 1 million weekly paid trips by the end of 2026. Without identifying where its robotaxis will be available next, Waymo is targeting a list of eight other cities that include Las Vegas, Washington, Detroit and Boston while signaling its first overseas availability is likely to be London.

To help pay for more robotaxis, Waymo recently raised $16 billion as part of the financial infusion that puts the value of the company at $126 billion. The valuation fueled speculation that Waymo may eventually be spun off from its corporate parent Alphabet, where it began as a secret project within Google in 2009.

Although Waymo is opening up in four more cities, its robotaxis initially will only be made available to a limited number of people with its ride-hailing app in Dallas, Houston, San Antonio and Orlando before the service will be available to all comers in those markets.

Tech giant Apple doubles down on Houston with new production facility

coming soon

Tech giant Apple announced that it will double the size of its Houston manufacturing footprint as it brings production of its Mac mini to the U.S. for the first time.

The company plans to begin production of its compact desktop computer at a new factory at Apple’s Houston manufacturing site later this year. The move is expected to create thousands of jobs in the Houston area, according to Apple.

Last year, the Cupertino, California-based company announced it would open a 250,000-square-foot factory to produce servers for its data centers in the Houston area. The facility was originally slated to open in 2026, but Apple reports it began production ahead of schedule in 2025.

The addition of the Mac mini operations at the site will bring the footprint to about 500,000 square feet, the Houston Chronicle reports. The New York Times previously reported that Taiwanese electronics manufacturer Foxconn would be involved in the Houston factory.

Apple also announced plans to open a 20,000-square-foot Advanced Manufacturing Center in Houston later this year. The project is currently under construction and will "provide hands-on training in advanced manufacturing techniques to students, supplier employees, and American businesses of all sizes," according to the announcement. Apple opened a similar Apple Manufacturing Academy in Detroit last year.

Apple doubles down on Houston with new production facility, training center Photo courtesy Apple.

“Apple is deeply committed to the future of American manufacturing, and we’re proud to significantly expand our footprint in Houston with the production of Mac mini starting later this year,” Tim Cook, Apple’s CEO, said in the news release. “We began shipping advanced AI servers from Houston ahead of schedule, and we’re excited to accelerate that work even further.”

Apple's Houston expansion is part of a $600 billion commitment the company made to the U.S. in 2025.

View All Listings